Congress caps what patients pay for prescription drugs at $2,000 yearly

What it does

This bill caps the annual out-of-pocket cost-sharing (copays, coinsurance, deductibles) that individuals must pay for prescription drugs covered by their health insurance plans. Starting in 2026, individuals cannot pay more than $2,000 per year for drugs, or $4,000 per family; the cap rises annually with medical inflation. The cap applies to all qualified health plans sold on the ACA marketplace, employer-sponsored group health plans, and self-insured plans.

Why we flagged it

The bill's sole operative mechanism is a direct cap on patient out-of-pocket drug costs across all major insurance channels (ACA marketplace, employer plans, self-insured plans). It is a consumer protection measure with no hidden provisions or carve-outs.

What the text implies

• Insurers and employers will face higher claims costs for prescription drugs; they may respond by narrowing formularies (covered drug lists), raising premiums, or increasing cost-sharing on non-drug services to offset.
• The cap applies only to cost-sharing on covered drugs — it does not address whether drugs are covered at all or subject to prior authorization, quantity limits, or step therapy.
• Effective date is plan years beginning January 1, 2026 — a 9-month implementation window for insurers and employers to reprogram billing systems and adjust plan designs.
• The bill does not address the underlying price of drugs, only patient cost-sharing; pharmaceutical manufacturers' revenues are unaffected by this cap.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people with health insurance gain a direct, enforceable limit on what they pay out-of-pocket for prescription drugs, reducing financial hardship from high drug costs. The cap is indexed to medical inflation, protecting purchasing power over time. No offsetting cost to citizens is apparent from the text.

Who stands to gain

• individuals and families with health insurance (reduced out-of-pocket drug costs)
• patients with chronic conditions requiring expensive medications

Named in the bill

Patient Protection and Affordable Care Act (ACA), Public Health Service Act, Employee Retirement Income Security Act (ERISA), Internal Revenue Code, Bureau of Labor Statistics, qualified health plans, group health plans, health insurance issuers, self-insured plans

Where it stands

9 cosponsors: 9 Democrats.

• Apr 1, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 1, 2025 — Referred to House Committee on Ways and Means and House Committee on Education and Workforce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,045,000 in lobbying spend. A filing names 41 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Steven Horsford, the sponsor, reported $1,775,734 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• American Kennel Club, Inc — $35,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.